Carbon nanotubes, used with near-infrared light and antibodies, hold promise for treating malignancies

ANTIBODY ATTACHMENTUsing a transmission electron microscope, scientists captured an image of antibodies attaching to carbon nanotubes. Each site consists of 10 to 25 antibody molecules.Balaji Panchapakesan/Univ. of Louisville in Kentucky
Covered in antibodies and bathed in laser light, carbon
nanotubes kill malignant cells with heat. The new technique may one day enable
physicians to target and kill cancerous growth without surgery, radiation or
chemotherapy.
After the team shone near-infrared light over a cell culture
with antibody-coated carbon nanotubes attached to cancer cells, the diseased
cells died, while non-cancerous cells went unharmed, researchers report online
June 16 in the Proceedings of the
National Academy of Sciences.
If this technique works in living tissue, “it might be
possible to cook tumors rather than to surgically remove them,” says Ellen
Vitetta, an immunologist at the University
of Texas Southwestern in Dallas and coauthor of the
new study.
Should future tests show this method is safe to use in
humans, doctors could inject antibody-coated carbon nanotubes into a breast
lump and then pass near-infrared light laser light over the skin. That would,
in theory, kill the tumor without invasive surgery.
“This research is at a very early stage,” Vitetta says, “so
moving it from a tissue culture setting to an animal and then a human is going
to take time. It might or might not work. It is too early to say.”

DEATH TO CANCER CELLSThe image on the left shows cancer cells not treated with antibody-coated nanotubes that survived the near-infrared light treatment. The image on the right shows cancer cells treated with antibody-coated nanotubes and light. The blue color indicates that the laser light killed the cell. Balaji Panchapakesan/Univ. of Louisville in Kentucky
Vitetta and her colleagues coated carbon nanotubes with leukemia-specific
antibodies that seek out and bind to particular molecules on human leukemia cells.
They then created lymphoma-specific antibodies and did the same in human
lymphoma cells. Each antibody type fits to only one kind of cancer cell, like a
key fitting only one lock, Vitetta explains.
Once the antibodies clicked into their targets, scientists
passed laser light over the cell culture. Like radio antennae, the carbon
nanotubes picked up the laser light’s frequency and converted the light to
heat, which heated, and ultimately killed, the cancer cells.
To make sure only diseased cells felt the heat, the team
conducted two control tests on healthy cells — one with a cell culture treated
only with laser light and one that also included the antibody-covered nanotubes.
In these trials, no cells were damaged.
“The controls are good. They serve as a rigorous test,” says
Eric Wickstrom, a biochemist at Thomas
Jefferson University,
in Philadelphia,
who studies how to use nanotubes and near-infrared light to destroy breast
cancer tissue but was not involved in the current study. “They answer whether a
specific antibody goes to a specific cancer cell, or whether any antibody will
do.”
The new study confirms Wickstrom’s team’s 2007 results,
which showed breast cancer cells could be killed with a similar method that
didn’t rely on specific antibodies. This team’s study shows that, using
cancer-specific antibodies, researchers could one day target and kill particular
types of cancer cells, Wickstrom adds.
That “proof of specificity” is the most significant aspect
of this work, Vitetta says.
Current cancer treatments, such as chemotherapy and
radiation, kill both diseased and healthy cells, Vitetta explains. This method could
cook only diseased cells, both dividing and dormant ones. According to Vitetta,
standard treatments do not kill dormant cancer cells.
These cells are not dividing at the time of treatment but
can do so at a later time and cause a relapse, Vitetta says. “Antibody-carbon nanotubes
would not care if a cell is dividing,” she says.
Found in: Biomedicine and Body & Brain
Please login or register to participate.